You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table.  

Characteristic Patient
1 2 3 4 5 6 7
Age,y/sex 28/F 37/F 55/F 20/F 57/M 31/F 27/F
Days from illness onset 3 2 10 5 3 4 3
Medical history Uncontrolled hyperthyroidism Unremarkable Influenza A(H3N2) virus encephalitis in 2012 Treated for Russell−Silver syndrome Unremarkable Recent breast implants Unremarkable
Leukocyte count, cells/mm3 2 2 10 5 2 3 13
CSF
   Protein, g/L 0.143 0.270 2.305 0.251 0.313 0.162 7.156
   Glucose, g/L 0.61 0.50 0.74 1.07 0.55 0.71 1.22
   Chloride, g/L ND ND 7.60 6.78 7.10 6.80 7.02
Virus type B seq EPI_ISL_179707 B seq EPI_ISL_179711 B B B seq EPI_ISL_182519 B B seq EPI_ISL_182518
Cerebral imaging result MRI, abnormal† CT, normal MRI, abnormal‡ MRI, normal MRI, normal NA MRI, abnormal§
Diagnosis Confirmed encephalitis Possible encephalitis Confirmed encephalitis Confirmed encephalitis Possible encephalitis Cerebellar ataxia Confirmed encephalitis
Length of hospitalization, d 7 9 18 17 10 5 3
Outcome Died Complete resolution Complete resolution Complete resolution Complete resolution Complete resolution Died
Clinical findings Fever, headache, sleepiness, left upper limb motor deficit, coma, GCS score 3–4 Fever, headache, sleepiness, photophobia, vertigo, stiff neck, positive Romberg sign Fever, confusion, photophobia, dizziness, right facial paralysis, aphasia, stiff neck, coma, GCS score 8 Fever, agitation, nystagmus, stiff neck, coma, GCS score 9–10 Fever, headache, dysarthria, right side motor deficit, vomiting Fever, headache, vomiting, vertigo, photophobia, ataxia, positive Romberg sign, movement and balance disorder Fever, headache, vomiting, lethargy, aphasia, upward deviation of eyes, seizures, coma, GCS score 3

Table. Characteristics of 7 patients with neurologic complications of influenza B virus infection, Romania*

*All patients showed negative RT-PCR results for influenza B virus in CSF. CSF, cerebrospinal fluid; CT, computed tomography; GCS, Glasgow coma scale; MRI, magnetic resonance imaging; NA, not available; ND, not determined.
†MRI on day 3. See Figure 1 for a detailed description.
‡MRI on day 8. See Figure 2 for a detailed description.
§MRI on day 2 showed multiple areas of hyperintensities.

CME

Neurologic Complications of Influenza B Virus Infection in Adults, Romania

  • Authors: Corneliu Petru Popescu, MD; Simin Aysel Florescu, MD, PhD; Emilia Lupulescu, MD, PhD; Mihaela Zaharia, MD; Gratiela Tardei, MD, PhD; Mihaela Lazar, MD, PhD; Emanoil Ceausu, MD, PhD; Simona Maria Ruta, MD, PhD
  • CME Released: 3/16/2017
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 3/16/2018, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for infectious disease clinicians, neurologists, internists, intensivists, and other clinicians caring for patients with influenza B-related neurologic manifestations.

The goal of this activity is to describe neurologic complications of influenza B virus infection in adults, based on a case series from a tertiary facility in Romania.

Upon completion of this activity, participants will be able to:

  1. Recognize clinical and neurologic manifestations of influenza B virus infection in adults, based on a case series from a tertiary facility in Romania
  2. Determine the course and treatment of influenza B virus infection in adults with neurologic complications
  3. Identify laboratory and neuroimaging findings of influenza B virus infection in adults with neurologic complications


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Authors

  • Corneliu Petru Popescu, MD

    Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania; ESCMID Study Group for Infectious Diseases of the Brain

    Disclosures

    Disclosure: Corneliu Petru Popescu, MD, has disclosed no relevant financial relationships.

  • Simin Aysel Florescu, MD, PhD

    Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania

    Disclosures

    Disclosure: Simin Aysel Florescu, MD, PhD, has disclosed no relevant financial relationships.

  • Emilia Lupulescu, MD, PhD

    National Institute of Research Cantacuzino, Bucharest, Romania

    Disclosures

    Disclosure: Emilia Lupulescu, MD, PhD, has disclosed no relevant financial relationships.

  • Mihaela Zaharia, MD

    Dr. Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania; ESCMID Study Group for Infectious Diseases of the Brain

    Disclosures

    Disclosure: Mihaela Zaharia, MD, has disclosed no relevant financial relationships.

  • Gratiela Tardei, MD, PhD

    Dr. Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania

    Disclosures

    Disclosure: Gratiela Tardei, MD, PhD, has disclosed no relevant financial relationships.

  • Mihaela Lazar, MD, PhD

    National Institute of Research Cantacuzino, Bucharest, Romania

    Disclosures

    Disclosure: Mihaela Lazar, MD, PhD, has disclosed no relevant financial relationships.

  • Emanoil Ceausu, MD, PhD

    Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania

    Disclosures

    Disclosure: Emanoil Ceausu, MD, PhD, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: MSD; Gilead

  • Simona Maria Ruta, MD, PhD

    Carol Davila University of Medicine and Pharmacy; Stefan S. Nicolau Institute of Virology, Bucharest, Romania

    Disclosures

    Disclosure: Simona Maria Ruta, MD, PhD, has disclosed no relevant financial relationships.

Editor

  • Thomas J. Gryczan, MS

    Copyeditor, Emerging Infectious Diseases

    Disclosures

    Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer, Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships:
    Owns stock, stock options, or bonds from: Pfizer

CME Reviewer

  • Robert Morris, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.


Accreditation Statements

This activity has been planned and implemented through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Neurologic Complications of Influenza B Virus Infection in Adults, Romania: Results

processing....

Results

Patients

Patient 1 was a 28-year-old woman who had uncontrolled hyperthyroidism, a 3-day history of high fever (temperature >39°C), headache, sleepiness, left upper limb motor deficit, and a Glasgow Coma Scale (GCS) score of 3−4/15. Results of cerebrospinal fluid (CSF) testing were unremarkable. The patient was intubated and mechanically ventilated after 4 hours of hospitalization.

Magnetic resonance imaging (MRI) of the brain (Figure 1) showed multiple areas of T2-associated hyperintensities associated with restricted diffusion with involvement of the genu corpus callosum bilateral internal capsule and several areas of white matter in the right frontal lobe. Hyperintensities were visible at the limit between the right parietal and occipital lobe (axial T2-associated and diffusion-weighted imaging), and multiple high-signal lesions associated with restricted diffusion were present in the right caudate nucleus head and the subcortical and deep white matter of the frontal lobes (coronal fluid–attenuated inversion recovery and diffusion-weighted imaging). Despite intensive antimicrobial drug treatment with oseltamivir, acyclovir, meropenem, mannitol, corticosteroids, and thyrozol, the patient died 7 days after admission.

Enlarge

Figure 1. Magnetic resonance imaging of the brain of a 28-year-old woman (patient 1) who had neurologic complications of influenza B virus infection, Romania. A) Axial T2 image showing multiple areas of T2-associated hyperintense lesions with involvement of the genu corpus callosum, bilateral internal capsule, and several areas of white matter in the right frontal lobe, and more discreetly at the limit between the right parietal and occipital lobe. B) Axial diffusion-weighted image showing restricted diffusion associated with lesions. C) Coronal fluid–attenuated inversion recovery image showing multiple hyperintense lesions in the right caudate head and the cortical and deep white matter of the frontal lobes. D) Coronal diffusion-weighted image showing restricted diffusion associated with lesions.

Patient 2 was a previously healthy 37-year-old woman who was hospitalized after 2 days of fever, rhinorrhea, myalgia that progressed to a headache, sleepiness, photophobia, vertigo, stiff neck, and a positive Romberg sign. Results of computed tomography (CT) and analysis of CSF were unremarkable. Complete resolution occurred after 9 days of treatment with oseltamivir and mannitol.

Patient 3 was a previously healthy 55-year-old woman with a history of influenza A(H3N2) virus encephalitis (in 2012). The patient was hospitalized after transfer from another clinic 10 days after onset of illness with signs and symptoms that included fever, confusion, photophobia, dizziness, right facial paralysis, aphasia, stiff neck, and coma (GCS score 8). Onset of neurologic signs occurred on day 5. Results of CT on day 7 were unremarkable. We found increased levels of proteins and cells in the CSF. Brain MRI showed symmetric diffusion restriction in the bilateral anterior frontal cortex (Figure 2). The patient was intubated and mechanically ventilated for 24 hours. She showed good progression after being given mannitol, dexamethasone, oseltamivir, and acyclovir. The patient was discharged with complete resolution after 18 days of hospitalization.

Enlarge

Figure 2. Magnetic resonance imaging of the brain of a 55-year-old woman (patient 3) who had neurologic complications of influenza B virus infection, Romania. Axial diffusion-weighted image showing restricted diffusion in the bilateral frontal cortex.

Patient 4 was a 20-year-old woman who had Russell−Silver syndrome and was being given prednisone and levothyroxine. She was admitted to an intensive care unit (ICU) already mechanically ventilated. Onset of illness was 5 days before admission and included fever, cough, and agitation. After 3 days in the hospital, nystagmus, stiff neck, and a GCS score of 9−10 were observed. Results of CSF testing and cerebral CT and MRI were unremarkable. She was given mannitol, methylprednisolone, and oseltamivir. Her condition improved after 17 days of hospitalization and was followed by complete recovery.

Patient 5 was a 57-year-old man who came to our clinic after 3 days of fever, chills, and cough. In the preceding 24 hours, headache, dysarthria, right side motor deficit, and vomiting developed. Results of CSF testing and cranial CT and MRI were unremarkable. The patient was given oseltamivir and mannitol. After 10 days, the patient was discharged, and he showed complete resolution.

Patient 6 was a 31-year-old woman who had recent breast implants. The patient was hospitalized after 4 days of fever, headache, vomiting, vertigo, photophobia, and movement and balance disorders. Results of CSF testing were unremarkable. She was given oseltamivir and mannitol, and her condition improved after 5 days.

Patient 7 was a 27-year-old woman who had influenza, fever, myalgia, headache, and vomiting 3 days before hospitalization. After 2 days, she became lethargic, had aphasia and seizures, and entered a coma; GCS score decreased to 3. Results of initial CSF testing were unremarkable. She was intubated, mechanically ventilated, and transferred to our clinic. Results of CT were unremarkable. However, MRI showed an abnormal result (multiple areas of hyperintensities).

At admission, patient 7 was comatose and intubated. She had unreactive fixed mydriasis, upward deviation of the eyes, and no corneal reflex and plantar cutaneous reflexes. Results of additional CSF testing showed pleocytosis and a high level of albumin (3.906 g/L). Renal failure and ventricular tachyarrhythmia developed. Despite treatment with oseltamivir, acyclovir, mannitol, methylprednisolone, and meropenem, the patient continued to show signs of brain death and died 3 days after admission.

Observations

The peak of the influenza season in Romania was during February−March 2015. A total of 110 patients with ILI (90 female patients and 20 male patients) were hospitalized at the tertiary care facility during January−April 2015. The median age of patients was 43 years (range 4−93 years); only 3 patients were <18 years of age. None of the patients had been vaccinated against influenza for the current season. There were 57 patients with ILI laboratory-confirmed influenza infection: 32 patients (56.2%) were infected with an influenza B strain, 14 (24.5%) with an influenza A/H3 strain, and 11 (19.3%) with the A(H1N1)pdm09 strain. These 3 strains were present in Romania at similar prevalences throughout the influenza season.

A complicated form of influenza was diagnosed for 28 (49.1%) patients, of whom 19 (33.3%) had respiratory complications (8 infected with the A(H1N1)pdm09 strain, 6 with the A/H3 strain, and 5 with the B strain), and 9 (15.7%) had neurologic complications (8 with the B strain and 1 with the (A/H1N1)pdm09 strain). Two patients who had febrile seizures as the only neurologic manifestation were excluded from analysis (1 child with a history of febrile seizures and 1 adult with epilepsy). Eight of the 9 patients with neurologic complications were female patients. Of those infected with an influenza B strain, 7 were adults (median age 31 years, range 20−57 years), and 1 was a 4-year-old girl. Six of the 7 adult patients infected with an influenza B strain in whom neurologic manifestations developed were women.

Antiviral treatment with a neuraminidase inhibitor (oseltamivir, 75 mg 2×/d for adults and 37.5 mg 2×/d for the child) was administered to all patients upon presentation. However, most patients presented late after onset of disease, and only 1 received oseltamivir within the first 48 hours of disease onset; the other patients received antiviral treatment 72 hours after disease onset.

Demographic, clinical, imaging and laboratory data for the 7 adult patients with neurologic manifestations and laboratory-confirmed influenza B virus infection are shown in the Table. None of the patients had preexisting neurologic diseases, and the average time from disease onset to hospitalization was 4.28 days. On the basis of the case definition, 4 patients were given a diagnosis of confirmed encephalitis (major criteria and ≥3 minor criteria and laboratory-confirmed influenza), 2 were given a diagnosis of possible encephalitis (major criteria and 2 minor criteria), and 1 was given a diagnosis of cerebellar ataxia (no major criteria but with neurologic manifestations).

Cerebral MRI was performed for 6 patients and CT was performed for 2 patients. Abnormal brain imaging results were observed for 3 patients: changes consistent with multiple areas of hyperintensities visible in T2-associated with restricted diffusion for patients 1 and 7 (patient 1; Figure 1) and cerebral edema and diffusion restriction for patient 3 (Figure 2). Six patients were admitted to the ICU; 4 of these patients required intubation and mechanical ventilation because of neurologic complications. Two patients died, 3 and 7 days after admission. The other 5 patients showed a good outcome with complete resolution. At a follow-up 1 month after discharge, results of neurologic examinations for the 5 patients were unremarkable without any signs or symptoms during this period.

Lumbar puncture was performed for all 7 patients. Results of CSF analysis were abnormal for 3 patients (pleocytosis [>5 cells/mm3] and increased protein levels). All CSF samples were negative for influenza virus nucleic acids, enteroviruses, and herpes viruses.

Genetic analysis of the HA sequences of influenza B viruses isolated from nasopharyngeal swab specimens was successful for 4 patients (patients 1, 2, 5, and 7) ( Table ). HA phylogenetic analysis showed that all strains belonged to Yamagata-lineage clade 3, representative strain B/Phuket/3073/2013, which is distinct from the World Health Organization recommended strain included in the 2014–2015 vaccine (B/Massachusetts/2/2012–like virus).